MediGene AG To Participate In Three International Conferences In January
Martinsried/Munich, 17 December, 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in three upcoming international investment, scientific and business development conferences:
• J.P. Morgan 33rd Annual Healthcare Conference
Date: 12 - 15 January 2015
Location: San Francisco, USA
• Biotech Showcase - 7th Annual Conference
Date: 12 - 14 January 2015
Location: San Francisco, USA
Company Presentation on 13 January 10 am (PST)
• Phacilitate Immunotherapie Forum 2015
Date: 26 - 28 January 2015
Location: Washington D.C., USA
Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG will chair the following events:
- 15-01-27: Seminar "Tailoring immunotherapies for patients with different stages of prostate cancer"
- 15-01-28: Panel discussion "What advancements can we expect in the short and longer term to optimize the specificity and selectivity of the next generation immunotherapeutic agents to deal with the diversity that is the tumor?"
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
Help employers find you! Check out all the jobs and post your resume.
• J.P. Morgan 33rd Annual Healthcare Conference
Date: 12 - 15 January 2015
Location: San Francisco, USA
• Biotech Showcase - 7th Annual Conference
Date: 12 - 14 January 2015
Location: San Francisco, USA
Company Presentation on 13 January 10 am (PST)
• Phacilitate Immunotherapie Forum 2015
Date: 26 - 28 January 2015
Location: Washington D.C., USA
Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG will chair the following events:
- 15-01-27: Seminar "Tailoring immunotherapies for patients with different stages of prostate cancer"
- 15-01-28: Panel discussion "What advancements can we expect in the short and longer term to optimize the specificity and selectivity of the next generation immunotherapeutic agents to deal with the diversity that is the tumor?"
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
Help employers find you! Check out all the jobs and post your resume.